Setmelanotide

About Soleno Therapeutics

Soleno Therapeutics is a mission-driven biopharmaceutical company focused on transforming the treatment landscape for rare genetic disorders. Its key achievement is the FDA approval and commercial launch of VYKAT XR (setmelanotide), the first and only therapy indicated for hyperphagia in Prader-Willi syndrome, marking its transition to a revenue-generating entity. The company's strategy leverages deep expertise in rare disease development and commercialization to maximize the potential of VYKAT XR while exploring its application in other indications within its core competency of melanocortin-4 receptor (MC4R) pathway disorders.

About Soleno Therapeutics

Soleno Therapeutics is a mission-driven biopharmaceutical company focused on transforming the treatment landscape for rare genetic disorders. Its key achievement is the FDA approval and commercial launch of VYKAT XR (setmelanotide), the first and only therapy indicated for hyperphagia in Prader-Willi syndrome, marking its transition to a revenue-generating entity. The company's strategy leverages deep expertise in rare disease development and commercialization to maximize the potential of VYKAT XR while exploring its application in other indications within its core competency of melanocortin-4 receptor (MC4R) pathway disorders.

About Soleno Therapeutics

Soleno Therapeutics is a mission-driven biopharmaceutical company focused on transforming the treatment landscape for rare genetic disorders. Its key achievement is the FDA approval and commercial launch of VYKAT XR (setmelanotide), the first and only therapy indicated for hyperphagia in Prader-Willi syndrome, marking its transition to a revenue-generating entity. The company's strategy leverages deep expertise in rare disease development and commercialization to maximize the potential of VYKAT XR while exploring its application in other indications within its core competency of melanocortin-4 receptor (MC4R) pathway disorders.

Therapeutic Areas